General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Public policy and advocacy

As a leading healthcare company, Novartis endeavors to actively participate in public policy debates affecting our business. We believe it is our responsibility to share our perspective, scientific knowledge and technical expertise and provide fact-based information to policymakers and regulatory authorities.

Responsible lobbying

Public policy and advocacy

In our lobbying and advocacy activities as in all other areas of our business we are governed by our Code of Conduct. Third parties who conduct advocacy on our behalf are subject to our Third Party Code.

We strive to engage in constructive debate with government and other stakeholders to improve outcomes for patients globally, while preserving incentives for research and innovation. Much of this work is done through trade associations, which can be a powerful vehicle for raising industry standards and exchanging best practice.

Novartis Group companies maintain full-time public affairs offices in:

  • Basel, Switzerland
  • Brussels, Belgium
  • Washington D.C., US

In many other countries where we operate, we have part- or full-time public affairs personnel. Our aim across all our offices is to monitor and assess regulatory and political decisions that may affect our business, to contribute to the policy process and to ensure consistency of action.

Political contributions

Political contributions are legitimate monetary or non-monetary contributions to support political organizations and candidates and their causes. All political contributions must be given in strict compliance with applicable laws, regulations, and industry codes. Political contributions must never be made with the expectation of a direct or immediate return for Novartis, and must always be made in compliance with local laws, regulations, and applicable industry codes.
Novartis is registered in the European Commission’s Register of Interest Representatives, a voluntary self-regulation system established by the European Commission. The register aims to increase transparency and is linked to a code of conduct. Novartis has committed to:

  • Publish an estimate of the costs associated with direct lobbying of the EU institutions incurred by in-house lobbyists
  • Subscribe to the Commission’s Code of Conduct or a comparable professional code

Novartis is also a proactive participant in the US political process, within the framework of the American legal system.

Corporations are prohibited from directly financing the campaigns of US candidates for federal office, but are allowed to form employee political action committees (PACs). The Novartis PAC is a bipartisan committee representing the Novartis Group, and supports candidates who share our views on issues important to the company.

The Novartis PAC supports candidates who:

  • Understand and support the Novartis mission to discover, develop and successfully market innovative products to prevent and cure diseases, ease suffering and enhance quality of life
  • Demonstrate leadership in key areas of importance to our business
  • Show dedication to improving the relationship between business and government
  • Have constituencies that include a Novartis facility or large employee demographic

Novartis adheres to the guidelines set forth by the United States Federal Election Commission (FEC) related to the federal campaign process.